证券日报网1月8日讯，恒坤新材在接受调研者提问时表示，光刻胶的替换对客户产品品质良率的影响很 大，将影响整个产品生态系统，客户需要愿意投入时间测试，验证材料与工艺的适配性，直至稳定供 货，时间可能长达3-4年。 ...

Core Insights - The Hong Kong Stock Exchange will officially launch the Hang Seng Biotechnology Index Futures on November 28, 2025, marking a significant milestone since the introduction of the Hang Seng Biotechnology Index [1] - The Hang Seng Biotechnology Index, launched in December 2019, aims to reflect the overall performance of biotechnology companies listed in Hong Kong that meet the Stock Connect eligibility criteria [1] - The index comprises 30 constituent stocks from four business subcategories: pharmaceuticals, biotechnology, pharmaceutical distribution, and medical devices and supplies [1] Performance Summary - As of December 5, 2025, the biotechnology sector accounts for 50% of the index weight, while pharmaceuticals account for 40% [1] - Over the past 12 months, the Hang Seng Biotechnology Index has increased by 76.8%, outperforming the Hang Seng Composite Index by 40 percentage points [1] - Year-to-date until December 5, the Hang Seng Biotechnology Index has risen by 80.4%, significantly higher than the Hang Seng Composite Index's increase of 33.8% by 46.6 percentage points [1] - The superior performance of the Hang Seng Biotechnology Index is attributed to policy support from mainland China and the growing global standing of Chinese biotechnology companies [1] Market Dynamics - The explosive growth in external licensing transactions (authorizing another entity to produce and/or distribute drugs) reflects the increasing importance of Chinese biotechnology companies, with transaction amounts rising from less than $100 million in 2019 to $52 billion in 2024, representing a compound annual growth rate of 249% [2] - Prior to the launch of the Hang Seng Biotechnology Index Futures, the Hong Kong Stock Exchange had introduced futures contracts based on three flagship indices: the Hang Seng Index, the Hang Seng China Enterprises Index, and the Hang Seng Technology Index [2] - Historical data indicates that as the product ecosystem around an index matures, trading volumes for its futures contracts tend to become more active [2]

Can you give us just your quick review of the event. Um, what you thought about the new iPhone 17 and why you think the stock traded lower. Well, look, I think it's always tough with Apple because the products are so good and and and looking at the product cycle.Clearly, these are best-in-class devices, but and so we were we were, you know, I thought the the iPhone 17 is is a great lineup. The Air is a fantastic new design. Um, and it all feels iterative, and that's true.We'd agree with that, but it comes f ...